For Immediate Release
MATCHPOINT SEARCH SOFTWARE ACCELERATES BOSTON CURE PROJECT'S EFFORTS TO CURE MULTIPLE SCLEROSIS
New York, N.Y. and Waltham, MA - November 18, 2003 - TripleHop Technologies, developers of the breakthrough MatchPoint 3.0 context-sensitive search software, today announced the Boston Cure Project for Multiple Sclerosis selected MatchPoint to help determine the causes of MS so a cure can be found.
The Boston Cure Project for MS, a national nonprofit, developed its Cure Map or organized plan of attack to: outline what is known and not known about the causes of MS, distinguish what researchers need to know, and to identify research activities required to determine the causes of MS.
Art Mellor, the CEO of the Boston Cure Project for Multiple Sclerosis, and an individual with MS says, "Before selecting MatchPoint, we relied solely on public search tools and Boolean search functionality, available on subscription sites, to find information on MS. Now with MatchPoint, we'll be able to accelerate Cure Map efforts by obtaining precise information as soon as it's made available, eliminating the need to sift through irrelevant query data."
To illustrate, a researcher at the Boston Cure Project investigating the environmental triggers of MS can use MatchPoint to perform a query against all available data sources (Internet, private subscription databases, and internal systems) regarding allergens and MS and receive a real-time, single list of relevant results.
Renaud Laplanche, CEO, TripleHop Technologies says, "Searching for data to help cure a debilitating disease is a critical task. We're pleased our technology will be used to support the Boston Cure Project's important efforts toward curing MS."
Multiple Sclerosis is a chronic demyelinating disorder of the central nervous system affecting over 400,000 people in the US and 2 million individuals worldwide. MS often results in severe disability including the inability to walk, blindness, cognitive dysfunction, extreme fatigue and other serious side effects. For more information about the Boston Cure Project or to make a contribution, call 781/788-0880, or visit www.bostoncure.org
About TripleHop Technologies, Inc.
TripleHop Technologies www.triplehop.com provides advanced context-search, retrieval and classification software solutions, giving users immediate access to the most relevant information by querying all enterprise repositories and delivering a single, unified list of results. Its award-winning MatchPoint enables users to access and share precise information from disparate sources, including the Internet, corporate networks, proprietary knowledge bases and digital media-improving productivity, yielding ROI and freeing-up time for other proactive activities. Customers include: USA Today, AOL Time Warner, a leading international law firm, a world leader in news and information delivery, Credit Mutuel, LVMH, Saint-Gobain and Orbitz.
About The Boston Cure Project
The Boston Cure Project for Multiple Sclerosis, www.bostoncure.org, is a national nonprofit organization dedicated to curing Multiple Sclerosis (MS) by determining its causes. Boston Cure Project believes this effort can be accelerated by organizing the research process and encouraging collaboration between research organizations and clinicians. A "Cure Map" is currently being developed by the Boston Cure Project to establish what is known and what is not known about the causes of MS. From the Cure Map, Boston Cure Project will facilitate research most likely to reveal the causes of MS in the shortest time through a large-scale, multidisciplinary, MS Repository. For more information about the Boston Cure Project or to make a corporate or individual donation, call 781/487-0008, visit bostoncure.org, or send an email to email@example.com.
About Multiple Sclerosis
Multiple Sclerosis is a chronic demyelinating disorder of the central nervous system that often results in severe disability including the inability to walk, blindness, cognitive dysfunction, extreme fatigue and other serious symptoms. MS affects over 400,000 people in the US and 2 million individuals worldwide. The disorder occurs twice as often in women as in men. The cause is not known and there is no known cure.